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Abstract
Small molecular PD-1 inhibitors are lacking in current immuno-
oncology clinic. PD-1/PD-L1 antibody inhibitors currently approved
for clinical usage block interaction between PD-L1 and PD-1 to
enhance cytotoxicity of CD8+ cytotoxic T lymphocyte (CTL).
Whether other steps along the PD-1 signaling pathway can be
targeted remains to be determined. Here, we report that methy-
lene blue (MB), an FDA-approved chemical for treating methe-
moglobinemia, potently inhibits PD-1 signaling. MB enhances the
cytotoxicity, activation, cell proliferation, and cytokine-secreting
activity of CTL inhibited by PD-1. Mechanistically, MB blocks inter-
action between Y248-phosphorylated immunoreceptor tyrosine-
based switch motif (ITSM) of human PD-1 and SHP2. MB enables
activated CTL to shrink PD-L1 expressing tumor allografts and
autochthonous lung cancers in a transgenic mouse model. MB also
effectively counteracts the PD-1 signaling on human T cells
isolated from peripheral blood of healthy donors. Thus, we identify
an FDA-approved chemical capable of potently inhibiting the func-
tion of PD-1. Equally important, our work sheds light on a novel
strategy to develop inhibitors targeting PD-1 signaling axis.
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Introduction
Antibodies against PD-1 or PD-L1 prevent interaction between PD-
1 and its ligand, block the activation of PD-1, and thereby restore
the activity of CTL to lyse PD-L1 expressing target cells and
shrink tumor in vivo (Hirano et al, 2005). Some of these antibod-
ies have been approved for clinical trial or usage (Dolan & Gupta,
2014). Impressive clinical benefit was seen in a portion of cancer
patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al,
2014).
Unfortunately, PD-1 inhibitors currently used in clinic show
severe, sometimes fatal, side effects (Johnson et al, 2016; Moslehi
et al, 2018). In contrast, PD-1-deficient mice of C57BL/6 back-
ground develop and grow apparently normally, with autoimmune
disease observed in late stage of their life (Nishimura et al, 1998,
1999). Lines of evidence suggest that the fragment crystallizable
regions (Fc region) of these antibodies play a role in mediating treat-
ment effect (Dahan et al, 2015). These data suggest that it is anti-
bodies, rather than PD-1 inhibition per se, that cause the side effects
currently seen in clinic. Small molecular PD-1 inhibitors are, there-
fore, expected to achieve therapeutic effect comparable to antibody
drugs while eliminating the toxicity issues. Unfortunately, small
molecular PD-1 inhibitors are lacking in the current immuno-
oncology clinic. Moreover, significant portion of the current PD-1
drugs inhibit PD-1 function through blocking interaction between
PD-1 and PD-L1. Whether other steps along the PD-1 signaling path-
way can be targeted to enhance cytotoxicity of CD8+ T cells remains
to be determined.
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Signaling pathways leading from binding of PD-L1/2 to PD-1
down to inhibition of T-cell activation and cytokine expression have
been relatively clear (Riley, 2009; Xia et al, 2016). Although SHP1
and SHP2 were earlier reported to be recruited by PD-1 to exert
immunoinhibitory function, it is been confirmed that SHP2 is the
main effecter (Yokosuka et al, 2012). Upon stimulation by PD-L1,
immunoreceptor tyrosine-based switch motif (ITSM) in the cytoplas-
mic tail of human PD-1 is phosphorylated on Y248, whereby provid-
ing a docking site for Src Homology 2 (SH2) domain of SHP2, which
is essential for interaction between PD-1 and SHP2 (Yokosuka et al,
2012). Reports have shown that phosphorylation of CD28 in T cells
is critical for mediating treatment effect of PD-1 inhibition (Hui et al,
2017; Kamphorst et al, 2017).
Protein–protein interactions (PPI) were previously considered
“undruggable” by small molecular chemicals. Recent mutational
study, however, revealed “hot spots” anchor residues that contrib-
uted the most to the binding free energy of the protein–protein
complex (Jin et al, 2014). By placing molecules at these sites,
orthosteric (i.e., competitive) small molecular inhibitors can effec-
tively block interaction of the targeted two proteins. Currently, PPIs
are targeted by an increasingly larger number of small molecular
chemicals (Ran & Gestwicki, 2018). Impressive successes have been
reported with inhibitors of protein–protein interactions (iPPIs) in
clinic as exemplified by Bcl-2 inhibitor, Venclexta (ABT-199) (Miha-
lyova et al, 2018).
Methylene blue (MB) is an FDA-approved small molecular drug,
used to treat patients with methemoglobin levels greater than 30%
or those who have symptoms despite oxygen therapy (Committee,
2015). It has previously been used for cyanide poisoning and
urinary tract infections, which is no longer recommended. MB is
known for its highly favorable safety profile as reflected in a recent
study showing that MB can be safely administered to reach a serum
concentration up to 6 lM (Baddeley et al, 2015).
In our current study, we report that MB effectively counteracted
the suppressive activity of PD-1 on CTLs and restored their cytotoxi-
city, activation, proliferation, and cytokine-secreting activity. Mech-
anistically, MB blocked interaction between SHP2 and Y248-
phosphorylated ITSM motif of human PD-1 and thus potently inhib-
ited the recruitment of SHP2 by PD-1 in CTLs when stimulated by
PD-L1. Impressive antitumor effect of MB was seen in allograft and
genetically engineered mouse tumor models. MB also recovered
proliferation and cytokine expression by human CD8+ T cells. Our
work therefore not only identified a potent small molecular iPPI for
blocking interaction between PD-1 and SHP2, but shed light on a
novel strategy for developing inhibitors targeting PD-L1/PD-1
signaling axis.
Results
MB enhances cytotoxicity of activated CTL against PD-L1
expressing target cells
We took advantage of engineered T-cell systems in which luciferase
gene was placed under control of NFAT binding sequence, such that
luciferase activity could serve as surrogate IL-2 mRNA transcription
(Chow et al, 1999). To identify a chemical PD-1 inhibitor through a
high-throughput screening, we generated a system composed of a
stable Jurkat T-cell line expressing human PD-1 and harboring
NFAT-luciferase reporter (designated JP-luc for Jurkat-PD-1-NFAT-
luciferase) and a stable Raji cell line (an antigen-presenting cell)
expressing human PD-L1 (designated Raji-L1) (Fig EV1A,
Appendix Fig S1A and B). When co-incubated with superantigen
SEE-loaded parental Raji, JP-luc exhibited robust luciferase activity.
In contrast, JP-luc showed limited luciferase activity when co-
cultured with SEE-loaded Raji-L1 (Appendix Fig S1C). Treatment
with PD-1 antibody (designated aPD1) recovered the luciferase
activity in JP-luc in the presence of SEE-loaded Raji-L1. We thus
established an efficient system to assay the intensity of PD-1 signal-
ing by monitoring luciferase activity of JP-luc (Appendix Fig S1C)
and whereby screened our chemical library. We identified 3,7-bis
(dimethylamino)-5-phenothiazinium chloride (also called methylene
blue; designated MB) as the best hit (Figs 1A and EV1B).
We then assayed MB’s ability to enhance cytotoxicity of PD-1
expressing CTL using in vitro cellular system. E.G7-OVA (designated
EG-7) is a cell line derived from spontaneous mouse thymoma cell,
EL-4, through stably transfecting with the complementary DNA of
chicken ovalbumin (OVA). This cell line presents OVA with an
H-2Kb-restricted CTL epitope (SIINFEKL) that is recognized by OT-1
transgenic TCR (Moore et al, 1988). We first generated an EG-7 cell
clone stably expressing PD-L1 (referred hereafter to as EG7-L1)
(Appendix Fig S1D). SIINFEKL peptide stimulation rapidly activated
splenic cells of OT-1 mice and expanded CD8+ T cells population to
a purity of almost 100% within 3 days (Appendix Fig S1E). OT-1
▸Figure 1. MB enhances cytotoxicity of activated CTL against PD-L1 expressing target cells.A Structural formula of 3,7-bis(dimethylamino)-5-phenothiazinium chloride (MB).
B Impact of MB on cytotoxicity of OT-1 CTLs against EG7 or EG7-L1. Splenocytes from OT-1mice in culture were stimulated with 10 nM of OVA257–264 (SIINFEKL) for 3 days to
generate mature CTLs. CTLs were incubated with CFSE-labeled EG7-L1 cells in the presence of MB at indicated concentrations. Cytotoxicity was determined by flow
cytometry analysis. Data are representative of three independent experiments (effector-to-target ratio = 5:1, unpaired t-test). EG7-L1: EG7 overexpressing PD-L1.
C Statistical results of (B).
D ELISA measured of LDH release to assess the cytotoxicity of OT-I CTLs on EG7-L1 in the presence of MB. Anti-PD1 antibody (aPD-1) served as positive control.
E Impact of MB on cytotoxicity of PD-1/ (PD-1KO) OT-1 CTLs against EG7 or PD-L1 expressing EG7 stable cell line. Data are representative of three independent
experiments (unpaired t-test).
F Statistical results of (E).
G Cytotoxicity of OT-I CTLs against B16-F10-OVA cells (designated B16-OVA) in the presence of 1 lM of MB or DMSO. Cytotoxicity was determined by the relative area
unoccupied by cells examined under microscope (scale bar = 50 lm). Data are representative of three independent experiments and were analyzed by unpaired
t-test.
H Statistical results of (G).
Data information: Data are representative of three independent experiments. Unpaired t-test; error bars denote SEM. **P < 0.01; ***P < 0.001; ****P < 0.0001.
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CTL rapidly upregulated PD-1 expression during this activation
(Appendix Fig S1F). We found that OT-1 CTL exhibited limited cyto-
toxicity against EG7-L1 target cells, which was significantly
enhanced by administration of aPD1 (Appendix Fig S1G, Fig EV1C
and D). FACS analysis showed that MB potently recovered cytotoxi-
city of CTL in a dose-dependent manner (Fig 1B and C). Moreover,
this cytotoxicity was repeated at various effector-to-target ratios
(Appendix Fig S1H and I). Of note, concentrations of MB in these
experiments are well below clinically achievable serum concentra-
tion. Moreover, we saw no cytotoxicity of MB at these concentra-
tions toward EG-7 cells (Appendix Fig S1J). Measuring lactate
dehydrogenase (LDH) released by target tumor cells into medium is
another accurate assay to determine CTL cytotoxicity (Decker &
Lohmann-Matthes, 1988). We quantified the LDH level in media
and confirmed the effectiveness of MB in enhancing cytotoxicity of
PD-1-positive OT-1 CTL against EG7-L1 (Fig 1D). To unequivocally
show that PD-1 was a critical target mediating the cytotoxicity
enhancing effect of MB, we repeated this experiment with OT-1
CTLs of PD-1/ (PD-1KO) background (Nishimura et al, 1998)
(Appendix Fig S1K and L). Critically, we found that MB treatment
did not further significantly enhance cytotoxicity of PD-1KO OT-1
CTLs against EG7-L1 (Fig 1E and F).
We went on to validate the effectiveness of MB to enhance cyto-
toxicity of OT-1 CTL against mouse melanoma cell B16-F10 (desig-
nated B16 cells). We confirmed the ability of IFNc to induce PD-L1
expression in B16 cells (Appendix Fig S1M). Earlier reports also
revealed that surface expression of MHC class I by B16 cells was
strikingly upregulated by IFNc (Bohm et al, 1998). Hence, OT-1 CTL
could only recognize and effectively kill IFNc-treated B16-OVA, but
not B16 cell or B16-OVA untreated with IFNc. Consistently, OT-1
CTL exhibited no obvious cytotoxicity against B16 or B16-OVA and
limited cytotoxicity against IFNc-treated B16-OVA while aPD1 treat-
ment significantly enhanced OT-1 CTL’s cytotoxicity against IFNc-
treated B16-OVA (Appendix Fig S1N and O). Using this system, we
found that administration of MB potently enhanced cytotoxicity of
OT-1 CTL against IFNc treated B16-OVA (Figs 1G and H, and
EV1E). Taken together, MB enhanced cytotoxicity of PD-1-positive
CTL against PD-L1 expressing target cells.
MB enhances proliferation and activation of CTL
Proliferation and activation are critical for function of CTLs. We
asked whether MB enhances both aspects of CTLs. We first checked
the ability of MB to promote proliferation of T cells in the presence
of PD-L1. CFSE-labeled splenic cells were stimulated with aCD3/
aCD28 and proliferation, as indicated by dilution of CFSE, of T cells
of wild type (WT), and PD-1KO background was analyzed 48 h after
stimulation through FACS analysis by gating on CD8+ population.
Data showed that proliferation of WT T cells was significantly
suppressed by PD-L1 treatment and this suppression was eliminated
by administration of aPD1 or MB (Fig EV2A and B, Appendix Fig
S2A). In contrast, neither MB nor aPD1 significantly enhanced prolif-
eration of PD-1KO CTLs, arguing that MB, just like aPD1, enhanced
proliferation of T cell through inhibiting PD-1 (Fig 2A and B).
We further checked the ability of MB to activate T cells.
Expression of CD25 (Theze et al, 1996) and CD69 (Santis et al,
1992) is 2 typical activation markers for T lymphocytes. We
found that splenic cells started to express CD25 when cultured in
aCD3/aCD28-coated plates, which was effectively suppressed by
PD-L1 treatment. aPD1 administration eliminated this suppres-
sion. FACS analysis revealed that 100 nM of MB potently recov-
ered CD25 expression in CTLs suppressed by PD-L1 in this
system (Fig 2C and D, Appendix Fig S2B). Similar effect was
seen on CD69 expression (Fig 2C and D). These data showed
that MB could restore the level of activation of CTLs suppressed
by PD-1.
MB enhances effector functions of CTL
T cells start to secrete IL-2 in response to TCR signaling. We used
JP-luc and Raji-L1 stable cell lines to quantitatively measure the
suppressive role of PD-1 signaling on IL-2 expression in T cells by
▸Figure 2. MB enhanced activation and effector function of CTL.A Effect of MB on the proliferation of WT CTLs and PD-1KO CTLs. Splenic cells were stained with 5 lM of CFSE and seeded into aCD3/aCD28-coated 96-well plates.
10 lg/ml of PD-L1 was administered in media. Cell proliferation was checked by monitoring dilution of CFSE 48 h after CD3/CD28 stimulation by gating on CD8-
positive population through FACS analysis. WT: splenic cell from wild-type C57BL/J mice. PD-1KO: splenic cell from PD-1 knockout mice.
B Statistical results of (A).
C FACS analysis of the effect of MB on the activation of OT-I CTLs. OT-I CTLs were stimulated with precoated aCD3/aCD28 and 10 lg/ml of mouse PD-L1 protein in the
presence of 100 nM MB or 10 lg/ml aPD1 (served as positive control). After 24 h, surface expression of CD25 and CD69 on OT-1 CTLs was determined through FACS
analysis.
D Statistical results of (C).
E Effect of MB on the activation status of Jurkat T cells. Luciferase activity is suppressed in JP-luc by co-culture with Raji-L1 preloaded with 1 lg/ml superantigen (SEE).
Treatment with MB enhanced luciferase expression (SEE-loaded Raji (PD-L1 negative) served as positive control). IC50 is calculated to be 117 nM. JP-luc: Jurkat cell
harboring NFAT-luciferase transgene and overexpressing PD-1; Raji-L1: Raji overexpressing PD-L1.
F Impact of MB on luciferase activity of various engineered Jurkat T cells. J-luc: Jurkat cell harboring NFAT-luciferase transgene; J-luc-sgPD-1: J-luc cells treated with
lentivirus expressing sgPD-1/CAS9 simultaneously.
G qRT–PCR analysis of IL-2 mRNA level in JP-luc cells stimulated with precoated aCD3/aCD28 (10 lg/ml) in the presence of 10 lg/ml of PD-L1 and MB at indicated
concentrations.
H MB enhancing IL-2 expression by JP-luc stimulated with Raji-L1 for 24 h quantified through ELISA analysis (aPD1 served as positive control).
I MB enhancing production of cytokine and cytolytic granule by OT-I CTLs. CTLs were incubated with EG7-L1 cells in the presence of protein transport inhibitor (PTI)
and MB at indicated concentrations. Expression of cytokine and cytolytic granule was determined by flow cytometry. aPD1 served as positive control. EG7-L1: EG7
overexpressing PD-L1.
J Statistical results of (I).
Data information: Data are representative of three independent experiments. Unpaired t-test; error bars denote SEM. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001.
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monitoring luciferase activity. In this system, MB potently counter-
acted the suppression imposed by PD-L1 on JP-luc with an IC50 of
117 nM (Fig 2E). Critically, in a parallel experiment with Jurkat
cells harboring NFAT-luciferase and CRISPR/CAS9-mediated
knockout of PD-1 (designated J-luc-sgPD-1), we found MB did not
further enhance luciferase activity (Fig 2F, Appendix Fig S2C).
The transcription of IL-2 mRNA was verified through qRT–PCR
(Fig 2G). We also confirmed secretion of IL-2 by measuring
protein concentration in the media through ELISA and found the
same pattern (Fig 2H).
We went on to check the ability of MB to enhance the expression
of key effector proteins, IL-2, perforin, IFNc, and granzyme B by
OT-1 CTL in the presence of PD-L1. As expected, aPD1 significantly
enhanced expression of effector molecules by CTLs stimulated with
EG7-L1 (Figs 2I and J, and EV2C–E). In a parallel experiment, we
found that MB dose-dependently enhanced protein level of IL-2 and
perforin (Fig 2I and J) and granzyme B and IFNc in T cells
(Fig EV2C–E).
Together, our data convincingly showed that MB restored
effector function of CTLs suppressed by PD-1.
MB inhibits the function of PD-1 through a novel mechanism
A significant portion of current PD-1 inhibitors function through
blocking interaction between PD-1 and its ligand. We went on test
whether MB blocked interaction between PD-1 and PD-L1. To this
end, we assayed the impact of MB on the binding of PD-L1-Fc fusion
protein to Jurkat-PD-1 cells through FACS analysis. However, we
found that MB did not interfere the binding of PD-L1 to PD-1
expressing cells (Fig EV3A, Appendix Fig S3A). Using purified
recombinant extracellular domain of PD-1 and PD-L1-Fc proteins,
we conducted an ELISA assay to quantify the impact of MB on bind-
ing of PD-L1 to PD-1 coated on plates. Results showed that MB did
not interfere interaction between both human and mouse PD-1 and
their respective ligands (Appendix Fig S3B). Thus, MB inhibited
function of PD-1 through a novel mechanism other than blocking
interaction between PD-1 and PD-L1.
MB suppresses PD-1 signaling through blocking recruitment of
SHP2 by PD-1
We then checked the inhibition of signaling events further down-
stream along the PD-1 pathway. PD-1 recruits SHP2 to inhibit the
TCR signaling when stimulated by PD-L1 (Riley, 2009; Yokosuka
et al, 2012; Xia et al, 2016). To find out whether MB interferes inter-
action between PD-1 and SHP2, we transfected Jurkat cells with
EGFP-tagged PD-1 and mCherry-tagged SHP2. Confocal micropho-
tography analysis confirmed cell membrane localization for EGFP
and cytoplasmic localization for mCherry, corresponding to cellular
localization of PD-1 and SHP2 in T cells (Fig 3A, Appendix Fig S3C–
G). Earlier reports showed that PD-L1 stimulation led to phosphory-
lation of Y248 in ITSM motif of PD-1, essential for recruitment of
SHP2 to inhibit TCR signaling (Yokosuka et al, 2012). Consistently,
we found that treatment of above transfected Jurkat cells with PD-
L1 resulted in Y248 phosphorylation of PD-1 (Appendix Fig S3H).
Moreover, PD-L1 treatment enhanced colocalization of mCherry to
membrane EGFP, indicating recruitment of SHP2 by PD-1 (Fig 3A,
Appendix Fig S3C–G). These results confirmed that our Jurkat
system recapitulated the physiological process of PD-1 signaling in
T cells. Using this assay system, we found that MB dose-depen-
dently blocked the colocalization of EGFP/mCherry induced by PD-
L1 treatment (Fig 3A, Appendix Fig S3C and D). We also found that
treatment with pervanadate (PVD), a potent nonselective phos-
phatase inhibitor, resulted in Y248 phosphorylation of PD-1 and
enhanced recruitment of SHP2 by PD-1 in Jurkat-PD-1-EGFP/
mCherry-SHP2 cells (Appendix Fig S3E and I). Importantly, MB
dose-dependently blocked the colocalization of EGFP/mCherry
induced by PVD treatment (Appendix Fig S3E–G).
To quantitatively measure the ability of MB to block interaction
between PD-1 and SHP2, we turned to bimolecular fluorescence
◀ Figure 3. MB suppress PD-1 signaling through blocking SHP2 recruitment by PD-1.A Confocal cell images of Jurkat cells co-expressing PD-1-EGFP and SHP2-mCherry. Jurkat cells co-expressing PD-1-EGFP and SHP2-mCherry were incubated with 10
lg/ml of human PD-L1 protein in the presence of 100 nM and 1 lM of MB for 2 min, fixed with 4% paraformaldehyde, and stained with DAPI. Colocalization signal
was examined with confocal microscope (scale bar = 2 lm).
B Fluorescence complementation analysis of the effect of MB on the interaction between PD-1 and SHP2. Jurkat cells co-expressing PD1-C-Luc or PD1Y248F-C-Luc and
SHP2-N-luc were seeded in a 96-well plate precoated with 10 lg/ml of aCD3/aCD28 with media supplemented with 10 lg/ml human PD-L1 protein in the presence
of MB at indicated concentrations for 6 h followed by analysis of luciferase activity.
C Co-IP analysis of impact of MB on interaction between PD-1 and SHP2. 293T cells co-expressing PD-1 and SHP2-FLAG were treated with MB at indicated
concentration for 6 h.
D Ability of MB to block interaction between PD-1 with SHP2 revealed through ELISA. Y248-phosphorylated human PD-1 ITSM peptide was coated at 4 lg/ml in 96-
well plate overnight. Recombinant human SHP2 protein incubated with the coated peptide in the presence of MB for 2 h. Bound SHP2 was measured by monitoring
the activity of horse peroxidase conjugated on secondary antibody targeting SHP2.
E Representative Western blot showing the levels of total and phosphorylated ZAP70, PKCh, and PLCc1 in the lysates of stimulated CTL, inhibited by PD-L1 in the
presence of 1 lM of MB.
F Representative Western blot showing the levels CD28 phosphorylation. CTL was stimulated with EG7 cells (parental), EG7-L1, and EG7-L1 in the presence of 100 nM
of MB for 2 h. Protein immunoprecipitated (IP) with anti-pY from the lysates of the indicated CTL-EG7 co-culture was subjected to SDS–PAGE separation and blotted
with aCD28. b-Actin served as loading control. EG7-L1: EG7 overexpressing PD-L1.
G Phos-tag analysis of CD28 phosphorylation in CTL. CTLs were stimulated with EG7 or EG7-L1 in the presence of 1 lM MB. Cell lysate was then separated by SDS–
PAGE containing 50 lM of Phos-tag and blotted with aCD28 antibody. Phosphorylated CD28 (slow-moving) species were visualized through exposure.
H Fluorescence complementation analysis of the effect of MB on the interaction between CD28 with P85. Jurkat or Jurkat-PD-1 cells were co-transfected with CD28-C-
Luc or CD28Y191F-C-Luc and P85-N-Luc. Cells were seeded in a 96-well plate coated with 10 lg/ml of aCD3/aCD28 in the presence of human 10 lg/ml of PD-L1
protein and 100 nM of MB for 6 h. Luciferase activity was measured as readout for CD28-P85 interaction.
Data information: Data are representative of three independent experiments and were analyzed by unpaired t-test. Error bars denote SEM. *P < 0.05; **P < 0.01;
****P < 0.0001.
Source data are available online for this figure.
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complementation assay (Shyu & Hu, 2008) by fusing PD-1 and
SHP2 to C- and N-terminal half of firefly luciferase respectively
(designated PD-1-C-luc and SHP2-N-luc, respectively). We then co-
expressed PD-1-C-Luc and SHP2-N-luc in Jurkat cells, such that
luciferase activity was a direct readout for interaction between PD-
1 and SHP2 in Jurkat cells. Result showed that MB potently inhib-
ited interaction of PD-1 with SHP2 elicited by PD-L1 treatment
(Fig 3B).
To further confirm the ability of MB to block interaction of SHP2
with Y248-phosphorylated PD-1 in an independent cell line through
luciferase complementation assay, we generated stable 293T-cell
clone co-expressing SHP2-N-luc and PD-1-C-luc (designated 293T-
SHP2/PD-1). We detected baseline PD-1 Y248 phosphorylation in
293T-SHP2/PD-1, which was dramatically enhanced by PVD treat-
ment (Appendix Fig S3J). PVD treatment enhanced luciferase activ-
ity in this 293T-SHP2/PD-1 cell line specifically depended on Y248
phosphorylation (Fig EV3B). We found that MB potently blocked
interaction between SHP2 and Y248-phosphorylated PD-1 in this
system (Appendix Fig S3K). We further sought to validate the ability
of MB to block interaction between PD-1 and SHP2 through co-IP
assay. To this end, we co-expressed SHP2-FLAG and PD-1 tran-
siently in 293T cells and subjected the cell lysate to immunoprecipi-
tation with FLAG antibody, followed by Western analysis with PD-1
antibody. We found that MB dose-dependently prevented interac-
tion of PD-1 and SHP2 (Fig 3C, Appendix Fig S3L). These results
solidly showed that MB functioned to prevent recruitment of SHP2
by PD-1.
To find out whether MB directly interfered the interaction
between PD-1 and SHP2, we conducted ELISA assay with synthe-
sized peptide covering Y248-phosphorylated ITSM of human PD-1
(designated Pep-ITSM-p248Y) and purified recombinant SHP2-Fc.
We found that MB dose-dependently blocked the binding of SHP2
protein to coated Pep-ITSM-p248Y, unequivocally showing that MB
directly blocked interaction between SHP2 and PD-1 (Fig 3D,
Appendix Fig S3M).
MB treatment enables effective TCR signaling in T cells
We then checked in detail the impact of MB on signaling events
downstream of TCR in OT-1 CTL. We found that MB treatment
restored phosphorylation of Akt, PLCc, PKCh, and ZAP70 in OT-1
CTL suppressed by PD-L1 treatment (Fig 3E).
CD28 phosphorylation in CTLs is a critical determinant of treat-
ment effect of PD-1 inhibitors (Hui et al, 2017; Kamphorst et al,
2017). We stimulated OT-1 T cells with EG-7 or EG7-L1, and total
cell lysate was subjected to pulldown with anti-phosphotyrosine
antibody followed by immunoblot with CD28 antibody to check
phosphorylation of CD28. Our data showed that MB strongly
enhanced phosphorylation of CD28 in OT-1 CTL suppressed by PD-
L1 (Fig 3F). Phos-tag SDS–PAGE is useful for separating a phospho-
rylated protein from its unphosphorylated counterpart by slower
moving rate (Nagy et al, 2018). We conducted Phos-tag SDS–PAGE
followed by Western analysis on lysate of the above OT-1/EG-7 co-
culture and found that MB potently and dose-dependently enhanced
phosphorylation of CD28 in OT-1 CTL (Fig 3G). We further showed
that MB treatment enhanced recruitment of P85 by CD28 (Fig 3H),
consistent with earlier report that activated CD28 recruited P85
(Tian et al, 2015). Moreover, we found that MB treatment resulted
in overall activation of T-cell function at transcriptomic level
(Appendix Fig S3N).
In line with our hypothesis that MB enhanced T-cell function
through blocking recruitment of SHP2 by PD-1, we consistently
found that MB did not significantly enhance luciferase activity in JP-
luc when SHP2 was knockout through CRISPR/CAS9 system (desig-
nated JP-luc-sgSHP2) or in the presence of SHP099, an SHP2-specific
inhibitor of phosphatase (Chen et al, 2016) (Fig EV3C,
Appendix Fig S3O). We also consistently found that MB did not
significantly enhance proliferation (Appendix Fig S3P and Q) and
IL-2 production of CTLs-sgSHP2 or CTLs treated with SHP099
(Appendix Fig S3R) and cytotoxicity of OT-1 CTLs-sgSHP2 or OT-1
CTL treated with SHP099 (Fig EV3D).
Taken our data together, we solidly showed that MB inhibited
PD-1 signaling by directly blocking its recruitment of SHP2 and thus
enabled effective TCR signaling.
MB is a specific iPPI for PD-1/SHP2 interaction
SHP2 plays a critical role mediating signaling of various receptor
tyrosine kinases (RTKs), either through direct binding in the case of
EGFR (Agazie & Hayman, 2003) or through adapter proteins in the
case of FGFR (Li et al, 2014). We asked whether MB inhibited inter-
action between SHP2 and RTKs, which could elicit severe side effect
if used in clinic. To this end, we transfected 293T cells with
constructs encoding SHP2 and EGFR or FGFR1 and checked the
impact of MB on interaction between SHP2 and these RTKs. Co-IP
experiment revealed MB had no detectable impact on the interaction
between SHP2 and EGFR (Fig EV3E). In a parallel experiment, we
also found no detectable impact of MB on binding between SHP2
and FGFR1 (Appendix Fig S3S). To further confirm our co-IP data,
we used luciferase complementation assay. We expressed SHP2-N-
luc and EGFR-C-luc or FGFR1-C-luc in 293T cells, such that luci-
ferase activity is a readout for interaction between SHP2 and corre-
sponding RTKs and checked the impact of MB on interaction
between SHP2 and RTKs through monitoring luciferase activity.
Results showed that MB did not inhibit the interaction between
SHP2 and EGFR (Appendix Fig S3T) or interaction between SHP2
and FGFR1 (Appendix Fig S3U). Taken together, our data strongly
suggested that MB specifically inhibited interaction between SHP2
and PD-1, but not the interaction between SHP2 and RTKs.
MB shrinks tumor in vivo through enhancing cytotoxic function
of CTL
PD-1 inhibitors have shown impressive treatment effect in clinic.
We went further to test the ability of MB to shrink tumors in vivo.
To this end, we inoculated EG7-L1 subcutaneously (S.C.) in C57BL/
6J mice on day 1 and intravenously (i.v.) injected activated OT-1
CTL on day 3 and 6, respectively, and randomized the mice into 3
groups (n = 5 for each group) for treating with vehicle, aPD1
(10 mg/kg, every other day, i.p.), and MB (20 mg/kg/day, i.g.),
respectively (Fig 4A). Tumor size was documented every other day
by calipering. While tumors in vehicle-treated group continued
growing, aPD1 or MB treatment shrank the tumor significantly in a
dose-dependent manner (Figs 4B and C, and EV4A). Tumor weight
of antibody-treated or MB-treated group was significantly lower
than that of vehicle-treated group by the end of treatment (Fig 4D).
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This result was repeated using OT-1 donor and host mice of RAG1/
background (Fig EV4B and C, Appendix Fig S4A–C), arguing that
antigen-specific CTLs were the critical elements for shrinking
tumors. Histologically, tumors showed high cellularity and tumor
cells showed higher nucleus/cytoplasm ratio in vehicle-treated
group. Moreover, cells of vehicle-treated tumor frequently took on a
spindle-like shape (Appendix Fig S4D, left panel). Occasional apop-
totic bodies were noticeable in hematoxylin-and-eosin-stained tissue
sections. These histological features suggested malignant nature of
tumor cells and tumor nodules in vehicle-treated mice. In stark
contrast, tumors were characterized with intra-tumoral spaces and
frequent apoptotic bodies in the aPD1- or MB-treated groups, indica-
tive of regression process (Appendix Fig S4D, middle and right
panel). CTL infiltration was significantly enhanced in tumors treated
with aPD1 or MB (Fig 4E, upper row, Fig 4F). Ki-67 staining
revealed that cell proliferation was inhibited in aPD1- or MB-treated
tumors in comparison with vehicle-treated group (Fig 4E, lower
panel, Fig 4F). To check the functional state of tumor-targeting CTLs
specifically, we transplanted OT-1 CTL of CD45.1 background into
CD45.2 host, such that tumor-infiltrating CD8+ OT-1 T cells could
be analyzed through FACS by gating on CD45.1-positive population
(Appendix Fig S4E). We found that MB treatment dramatically
enhanced expression of perforin, granzyme B (GZMB), and IL-2 by
CTL in tumor nodules (Fig 4G and H). In line with our hypothesis
that MB activated T-cell function through inhibiting PD-1 signaling,
we found that PD-1KO OT-1 CTL on its own shrank tumor allografts
and that MB treatment did not further significantly shrink the tumor
volume (Fig EV4D, Appendix Fig S4F).
We went further to model cancer patients with transgenic mouse
models of autochthonous lung cancer. We generated TetO-EGFR
L858R/CC10rtTA bitransgenic mice (designated EC mice) following
our earlier protocol (Ji et al, 2006). EC mice developed lung adeno-
carcinoma after being fed with doxycycline-containing diet for
2 weeks (Appendix Fig S4G–I). Clinical data have shown that PD-1
antibodies are not effective in treating EGFR mutation-positive lung
cancer patients (Yoshida et al, 2018). Consistently, we found that
aPD1 administration showed no noticeable treatment effect on EC
tumors (Appendix Fig S4J and K). In striking contrast, we found that
MB treatment led to dramatic regression of EC tumors (Fig 4I–K).
Depleting CD8+ T cells with aCD8 antibody (Appendix Fig S4L)
largely eliminated the tumor shrinking effect by MB (Fig 4J–M),
indicating that CD8+ T cells played a critical role in mediating the
treatment effect of MB. FACS analysis revealed that tumor-infil-
trating CD8+ T cells in the MB treatment group secreted more IL-2,
granzyme B, and perforin (Fig EV4E). Of note, MB was not toxic to
EGFR mutant lung cancer cells at concentrations reached at serum
level and shows limited toxicity to these cells at super-physiological
concentrations (Appendix Fig S4M and N).
Together, our data showed that MB shrank the tumor through
activating CD8 cytotoxic T cells in vivo.
MB effectively activates human CD8 T cells
We further asked whether MB was effective in enhancing human T-
cell function. To this end, we isolated human peripheral blood
mononuclear cells from healthy donors for CFSE dilution assay and
quantified the impact of MB on the proliferation of CTLs in the pres-
ence of PD-L1 through FACS analysis by gating on CD8+ populations.
In this experiment, we compared the PD-1 inhibiting activity of MB
with pembrolizumab and nivolumab, 2 most popular PD-1 antibodies
currently used in clinic. Result showed that in the presence of PD-L1,
100 nM of MB elicited stronger proliferation of CD8+ T cells than
25 lg/ml of pembrolizumab or 20 lg/ml nivolumab, respectively
(serum concentration achievable in patients for pembrolizumab (Pat-
naik et al, 2015) and nivolumab (Brahmer et al, 2010), respectively)
(Figs 5A and EV5A, Appendix Fig S5A). Consistently, MB effectively
counteracted PD-L1 on suppression of IL-2, IFNc, perforin, and gran-
zyme B expression in CD8+ T cells (Figs 5B and EV5B–E).
We also quantitatively measured ability of MB to counteract the
inhibition imposed by PD-L1 on T cells using JP-luc and superanti-
gen SEE-loaded Raji-L1. Based on this system, 100 nM of MB stimu-
lated similar luciferase activity to 25 lg/ml of pembrolizumab or
20 lg/ml of nivolumab. 1 lM or larger amount of MB stimulated
stronger luciferase activity than those by antibodies (Fig 5C). These
data solidly showed that MB effectively activated human CD8+ T
cells.
▸Figure 4. MB shrinks tumor in vivo through enhancing cytotoxic function of CTL.A Schematic of the xenograft mouse model for MB treatment. C57BL/6J mice were inoculated with EG7-L1 cells (2 × 106 cells, s.c.) on the right flank on day 1, followed
by injection (2 × 106 cells, i.v.) of CD45.1+ CTL on day 3 and 6, respectively. The mice were randomized into three groups (n = 5) and treated with vehicle, MB (20 mg/
kg/day, i.g.), and aPD1 (10 mg/kg, every other day, i.p.) served as positive control. Tumor size was measured through calipering every other day. EG7-L1: EG7
overexpressing PD-L1.
B Tumor growth curve for (A) was shown as mean  SEM.
C Representative image of the tumor on day 10 mentioned in (A).
D Tumor weight on day 10 (n = 5) mentioned in (A).
E Immunohistochemical analysis of cell proliferation marker ki-67 and CD8 in tumor nodules on day 10 (n = 5) in (A).
F Statistical results of (E).
G Expression of perforin, GZMB, and IL-2 by CD8+ CD45.1+ TILs was analyzed by flow cytometry.
H Statistical results of (G).
I Schematic of EGFR L858R mice treated with MB.
J Tumor burdens recorded through computed tomography (CT) scanning for EGFR L858R mice (n = 5, lung section = 3). Mice were treated with MB (20 mg/kg/day, i.g.)
for 1 week, followed by imaged with CT again to record tumor burden.
K Statistical results of (J).
L Hematoxylin and eosin staining of lung section of EGFR L858R mice (n = 5, lung section = 3) in (J).
M Statistical results of (L).
Data information: Data are representative of three independent experiments and were analyzed by unpaired t-test. Error bars denote SEM. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001.
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Discussion
Small molecular PD-1 inhibitors are urgently needed in immuno-
oncology clinic. Small molecular drugs outperform antibody drugs
with higher penetrating abilities into the interstices of a tumor and
targeting intracellular signaling proteins. The procedure for synthe-
sis, purification, and molecular characterization of small molecules
guarantees their identity and purity, ensuring them easy to repro-
duce. In addition, developing effective chemical PD-1 inhibitors will
not only lower cost, but free patients from intravenous injections.
Indeed, MB exhibited superior treatment effect on EGFR L858R-
driven lung cancers in our transgenic mouse model where PD-1
antibody failed to show treatment effect. Likewise, CD8+ T cells in
the tumors of MB-treated EG7-L1 allograft tumor model expressed
higher levels of effector molecules than those in PD-1 antibody-
treated mice. Small molecular drug is therefore a highly promising
field for developing PD-1 inhibitors.
Earlier, targeting interaction between PD-1 and PD-L1 has been
tried (Zak et al, 2016), including CA-170 (Bojadzic & Buchwald,
2018), BMS-1001 and BMS-1166 (Skalniak et al, 2017), and peptides
(Chang et al, 2015; Li et al, 2018). The clinical performance of these
drugs remains to be determined. More studies are needed to deter-
mine whether other steps along the PD-1 signaling pathway could
be targeted by small molecules. Our current work identified MB as a
potent PD-1 inhibitor through a high-throughput screening. Mecha-
nistic study revealed that MB inhibited PD-1 signaling by blocking
recruitment of SHP2 by PD-1. Moreover, MB is effective to enhance
cytotoxicity of CTLs in vitro and in vivo. Our work, therefore, not
only characterized a potent small molecular PD-1 inhibitor of
substantial possibility to benefit cancer patients immediately (for it
is an FDA-approved drug), but presents a novel strategy to develop
PD-1 inhibitors. This novel strategy will undoubtedly broaden our
choice for developing PD-1 inhibitors.
MB is used to treat patients with methemoglobin levels greater
than 30% or those who have symptoms despite oxygen therapy
(Committee, 2015). As a drug with a long clinical history, MB is
famous for its favorable safety profile. In a 2-year-treatment toxicity
study, researchers found that MB-treated mice survived longer than
vehicle-treated group (Hejtmancik et al, 2002). Other studies have
also shown that MB exhibited favorable clinical safety profile (Bad-
deley et al, 2015). Given the facts that the serum concentration
reached in patients is around 6 lM (Baddeley et al, 2015) and that
IC50 to effectively enhance cytotoxicity of CTL is well below micro-
molar, it is a tempting hypothesis that MB be a highly effective PD-1
inhibitor in clinic for treating cancer patients either by itself or in
combination with other drugs. MB is, therefore, an attractive candi-
date for clinical trial for cancer and other related disease.
Our work showed that MB inhibited SHP2 to function down-
stream of PD-1 in CTLs in response to PD-L1 stimulation. SHP2
phosphatase inhibitors are expected to possibly enhance CTL func-
tion based on the fact that SHP2 negatively impacts on TCR signal-
ing.
We noticed the difference in baseline functions of sgSHP2-
versus SHP099-treated T cells. For examples, when co-cultured
with SEE-loaded Raji cells, SHP099-treated JP-luc expressed higher
luciferase activity than JP-luc-sgSHP2; when stimulated with
aCD3/CD28-coated plate, CTL treated with SHP099 proliferated
more than CTL-sgSHP2; SHP099-treated CTL expressed higher
amount of IL-2 than CTL-sgSHP2; and SHP099-treated OT-1 CTL
kills EG7-L1 more efficiently than OT-1-sgSHP2. Recently, Rota
et.al. reported that SHP2 was apparently dispensable PD-1 signal-
ing in vivo (Rota et al, 2018). How could we reconcile this incon-
sistency? PD-1 predominantly recruits SHP-2 (Yokosuka et al,
2012), with details for signaling worked out very recently (Marasco
et al, 2020). In the case of SHP2 knockout, PD-1 recruits SHP-1
and remains functional (Celis-Gutierrez et al, 2019). In line with
this rationale, SHP2-deficient T cells could behave similarly to WT
T cells. It could well be that SHP099 inhibited SHP2 protein
prevents the compensatory recruitment of SHP1 by PD-1; thus,
TCR signaling is more robust.
In summary, we identified an FDA-approved drug as a potent
PD-1 inhibitor. Equally important, we showed that targeting PD-1/
SHP2 interaction was a realistic strategy for developing PD-1
inhibitors.
Materials and Methods
Plasmid constructs, transfection, and viral packaging
pCDH-NFAT-luc for delivering 3×NFAT binding sequence-controlled
luciferase fragment through virus infection: Backbone of pCDH (Sys-
tem Biosciences, CD500B-1) was digested with SpeI and NotI. DNA
fragment featuring luciferase controlled by 3 repeats of NFAT bind-
ing sequence (designated NFAT-luc) was synthesized. pCDH back-
bone and NFAT-luc fragment were assembled by T4 ligase.
pCAGiN-hPD-1/hPD-L1 (human PD-1, human PD-L1) for high
expression of hPD-1 and hPD-L1. pCAGiN (Addgene, #13461) was
◀ Figure 5. MB is effective to activate human CD8+ T cells.A Effect of MB on proliferation of human CD8+ T cells. CFSE-labeled human peripheral blood mononuclear cells (PBMC) were preincubated with DMSO, MB, 25 lg/ml of
pembrolizumab, or 20 lg/ml of nivolumab for 1 h and then seeded in the 96-well plate precoated with 10 lg/ml of aCD3/aCD28 in the presence of 10 lg/ml human
PD-L1 protein. Cell proliferation was analyzed through FACS analysis of dilution of CFSE.
B Cytokine and cytolytic granule production in CD8+ T cells. Human peripheral blood mononuclear cells from healthy donators were stimulated with 5 lg/ml of
phytohaemagglutinin for 2 days and then rested for 1 day. Cells were pretreated with DMSO, MB, 25 lg/ml of pembrolizumab (Pem), or 20 lg/ml of nivolumab (Niv)
for 1 h and then seeded in a 96-well plate precoated with 10 lg/ml aCD3/aCD28, with media supplemented with 10 lg/ml of human PD-L1 protein. Cytokine and
cytolytic granule production was determined by intracellular flow cytometry by gating on CD8+ populations.
C Comparison of the efficacy of MB with PD1 inhibitors currently used in clinic to activate T cell. JP-luc cells were stimulated with Raji-L1 or parental Raji cells
preloaded with 1 lg/ml of superantigen (SEE) in the presence of MB at indicated concentration or 25 lg/ml of pembrolizumab (Pem) or 20 lg/ml of nivolumab (Niv)
for 6 h. Luciferase activity was measured by luminometer. Data are representative of three independent experiments and were analyzed by unpaired t-test. JP-luc:
Jurkat cell harboring NFAT-luciferase transgene and overexpressing PD-1; Raji-L1: Raji overexpressing PD-L1.
Data information: Data are representative of three independent experiments and were analyzed by unpaired t-test. Error bars denote SEM. **P < 0.01; ****P < 0.0001.
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digested with EcoRI and ClaI. EcoRI and ClaI flanked hPD-1 and
hPD-L1 were synthesized. Digested hPD-1 and hPD-L1 were
subcloned into identically digested pCAGiN, respectively.
pcDNA3.1-hPD-1-EGFP and pcDNA3.1-hSHP2-mCherry (human
SHP2) for colocalization assay: Fragments hPD-1-EGFP and hSHP2-
mCherry were synthesized. pcDNA3.1 was digested with Knp1 and
Asc1. hPD-1-EGFP and hSHP2-mCherry fragments were identically
digested for cloning into pcDNA3.1.
pWPI-mPDL1 (mouse-PDL1) for overexpression of mPD-L1 and
IRES-EGFP element in the vector for FACS sorting virus-infected
cells: pWPI (Addgene, #12254) and mPD-L1 fragment was digested
with SwaI and AscI and joined by T4 ligase.
pCAGiN-hPD-1-C-luciferase for overexpressing fusion gene
containing hPD-1 followed by C-terminal half of luciferase. HindIII
and Asc1 double digestion modified hPD-1 and pCAGiN-C-luciferase
were joined by T4 ligase.
pCAGiP-N-luc-hSHP2 for overexpressing fusion gene containing
N-terminal half of luciferase followed by hSHP2 gene fragment. The
pCAGiP vector is digested with EcoRI/CIP and blunted with Klenow.
N-luc-SHP2 fragment and pCAGiP were joined by T4 ligase.
Lentivirus packaging: co-transfecting pCDH-NFAT-luc, psPAX2,
and PMD2.G (Addgene, deposited by Didier Trono, #12260 and
#12259) into HEK293T cells using transfection reagent VigoFect
(Vigorous Biotechnology, Beijing, China). The culture was replaced
with fresh media 6–8 h after the transfection. The supernatant was
harvested 48 h after media change and sterilized through a 0.45 lm
filter. The recombinant virus stock was stored at 80°C until use.
Delivering plasmid into cells through electroporation: Instructions
of Neon transfection system (Thermo, MPK5000) was strictly
followed. Briefly, incubating cells in a single well of 6-well plates
with 2 ml of culture medium containing serum and supplements
without antibiotics in a humidified incubator at 37°C and 5% CO2.
Pelleting cells (Jurkat E6-1 or Raji cells) by centrifugation at 100–
400× g for 5 min at room temperature (RT). Washing cells with PBS
(without Ca2+ and Mg2+) and resuspending in Resuspension Buffer
R at a final density of 2.0 × 107 cells/ml. Gently pipetting the cells to
obtain a single cell suspension. Mix 10 lg plasmid DNA with 100 ll
cells (2.0 × 107 cells/ml) in Resuspension Buffer R at RT and electro-
porating at 1,350 v, 10 ms, 3 pulses for Jurkat E6-1 cells or 1,300 v,
30 ms, 1 pulse for Raji. Slowly removing the Neon Pipette from the
Neon Pipette Station and immediately transferring the samples into
the prepared culture plate containing prewarmed medium.
The gRNA targeting sequences used in this study were as
follows:
Human PD-1-gRNA: GGCCAGGATGGTTCTTAGGT (Ren et al,
2017);
Human SHP2-gRNA: CTGGACCAACTCAGCCAAAG;
Mouse SHP2-gRNA: GAGGAACATGACATCGCGG (Ruess et al, 2018).
Cell culture and cell lines
All cell lines were maintained in standard tissue culture incubators
at 37°C and 5% CO2. Jurkat E6-1 and Raji cells were cultured in
RPMI-1640 supplemented with 10% fetal bovine serum (FBS, Gibco,
42G9274K) and 1% penicillin/streptomycin/glutamine (Gibco,
15140122). 293T cells were cultured in DMEM supplemented with
10% calf serum and 1% penicillin/streptomycin/glutamine.
We used the recombinant pWPI-mPDL1 lentivirus to infect EG7
cells for 24 h, replaced with fresh media, and sorted the mPD-L1+
cells by flow cytometer with mPDL1-PE (1:100, eBioscience, 12-
5982-81) to derive mPD-L1 expressing EG7 stable cell line (desig-
nated EG7-L1). We transfected pCAGiN-hPD1 and pCAGiN-hPDL1
into Jurkat E6-1 and Raji cells, respectively. hPD1- and hPD-L1-posi-
tive cells were sorted with hPD1-FITC (1:100, BioLegend, 329904)
and hPDL1-PE (1:100, BioLegend, 329706) and seeded at single cell/
well in 96-well plate to derive stable cell clones (Jurkat-hPD-1 T-cell
line and Raji-L1, respectively). Then, Jurkat-hPD-1 T-cell line
infected with recombinant pCDH-NFAT-luciferase lentivirus to
generate Jurkat-hPD-1-NFAT-luciferase cell line (designated JP-luc).
Jurkat cells transiently co-expressed hPD-1-EGFP and hSHP2-
mCherry were generated by electroporating both plasmids into
Jurkat cells.
Antibodies and flow cytometry
The single cell suspension was prepared by mechanic grinding of
indicated tissues. For surface marker staining, cells were resus-
pended at 1 × 106 per 100 ll PBS and stain cells with 1ul of antibody
solution. Namely, CD8 (1:100, BD Horizon, 564297), CD45.1 (1:100,
BioLegend, 110706), CD45 (1:100, BD Horizon, 557659), and CD8
(1:100, BioLegend, 100738) were used to stain cells at 4°C for 30 min
in dark. Intracellular staining kit (eBioscience, 00-5523-00) was used
for staining intracellular target proteins following the instructions
provided by manufacturer. Cells were resuspended with 500 ll of
1× Fix buffer and kept at room temperature in dark for 30 min or at
4°C overnight. These cells were then washed with 500 ll of
1× permeabilization wash buffer and centrifuged at 395 g for 5 min.
Cell pellets were resuspended with 100 ll of 1× permeabilization
wash buffer. Then, add 1 ll antibodies solution for staining perforin
(1:100, eBioscience, 17-9392-80), IL-2 (1:100, eBioscience, 12-7021-
82), or GZMB (1:100, BioLegend, 515408) by incubating at room
temperature for 45 min in dark. Stained cells were washed with 1 ml
of 1× permeabilization buffer before analysis by FACS.
Immunohistochemistry analysis
Xenograft and lung tissues were fixed with 10% neutral buffered
formaldehyde overnight. Paraffin sections were stained with hema-
toxylin and eosin or subjected to immunohistochemistry for CD8
(1:50, Cell Signaling Technology, 98941) or ki-67 (1:500, Abcam,
ab15580).
Measurement of OT-1 CD8+ T-cell cytotoxicity
Splenocytes isolated from OT-I mice were stimulated with OVA257–
264 for 3 days in the presence of 10 ng/ml of IL-2 to generate mature
CTLs. Cells were centrifuged and cultured in fresh medium contain-
ing 10 ng/ml of IL-2 for 2 more days. To measure CD8+ T-cell cyto-
toxicity, we mixed CTLs and CFSE (eBioscience, 65-0850-84)-
labeled EG7-L1 cells in the presence of MB at indicated concentra-
tions (1 × 104) in the killing medium (LDH: phenol-free RPMI 1640,
2% FBS; FACS with PI or DAPI: RPMI 1640, 10% FBS) at the effect
to target ratios of 2:1, 5:1, and 10:1, respectively. After 4 h, the cyto-
toxic efficiency was measured by quantifying the lactate dehydroge-
nase (LDH) in media using a CytoTox 96 Non-Radioactive
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Cytotoxicity kit (Promega, G1780). Alternatively, apoptotic EG7-L1
cells were stained with PI (10 lg/ml) or DAPI (5 lg/ml) and
analyzed by flow cytometry by gating on CFSE/PI or CFSE/DAPI
double-positive populations.
Measurement of cytokine production by OT-I CTL cells
CTLs were cultured and pretreated with protein transport inhibitor
(PTI) and DMSO for 1 h at 37°C and 5% CO2 before incubating with
CFSE-labeled EG7-L1 cells for 6 h. Cells were fixed with 4%
paraformaldehyde (PFA) and permeabilized with saponin (Sigma,
47036) and stained with IL-2-PE (1:100, eBioscience, 12-7021-82),
IFNc-PE-Cy7 (1:100, eBioscience, 25-7311-82), perforin–APC (1:100,
eBioscience, 17-9392-80), or GZMB-Alexa Fluro (1:100, BioLegend,
515405). Cytokine production was measured by flow cytometric
analysis gating on CFSE negative population.
CD8+ T-cell proliferation
In Fig 2A, splenocytes isolated from OT-I mice were labeled with
5 lM of CFSE and seeded in a 96-well plate precoated with 10 lg/
ml of aCD3/aCD28 and with culture media supplemented with
mPD-L1 protein (Fc tag, Sino Biological, 50010-M03H-10) in the
presence of 100 nM of MB or 10 lg/ml of aPD1 antibody. Cells were
stained with CD8-PE (1:100, eBioscience, 12-0081-81). CTL prolifer-
ation was measured by CFSE dilution through FACS by gating on
CD8-positive population.
In Fig 5A, human peripheral blood mononuclear cells from
healthy donors were labeled with CFSE and seeded in a 96-well
plate precoated with 10 lg/ml of aCD3/aCD28 and with culture
media supplemented with 10 lg/ml hPD-L1 protein (Fc tag, Sino
Biological, 10084-H02H-100) in the presence of 100 nM of MB or
25 lg/ml of pembrolizumab or 20 lg/ml nivolumab (kindly gifted
by Dr. Li Zhang, SYSUCC). Cells were stained with CD8-PE (1:100,
eBioscience, MHCD0804) after 24 and 48 h of incubation. CTL
proliferation was measured by CFSE dilution through FACS by
gating on CD8 positive population.
Measurement of cytokine production by human CD8+ T cell
Human peripheral blood mononuclear cells from healthy donators
were stimulated with 5 lg/ml phytohaemagglutinin (Sigma) for
2 days and then rested for 1 day. Cells were pretreated with DMSO
or MB or 25 lg/ml pembrolizumab or 20 lg/ml nivolumab for 1 h
and then seeded in a 96-well plate precoated with 10 lg/ml of
aCD3/aCD28, with media supplemented with 10 lg/ml of hPD-L1
protein. Cells were fixed with 4% paraformaldehyde (PFA) and
permeabilized with saponin (sigma, 47036). Cells were stained with
CD8-FITC (1:100, eBioscience, 11-0081-82), IL-2-PE (1:100, BioLe-
gend, 500306), IFNc-PE (1:100, BioLegend, 502508), perforin-PE
(1:100, BioLegend, 353303), or GZMB-Alexa Fluro (1:100, BioLe-
gend, 515405), and cytokine production was measured by flow cyto-
metric analysis by gating on CD8-positive population.
Jurkat stimulation assay
For Jurkat cell stimulation assay shown in Fig 2E and F,
Appendix Fig S1C and Fig 5C, Jurkat-PD-1 cell transfected with
NFAT-luciferase reporter (designated JP-luc) was generated. Raji
stably expressing hPD-L1 was generated (designated Raji-L1) as
antigen-presenting cells (APC). Raji cells or Raji-L1 cells were prein-
cubated with 1 lg/ml of SEE superantigen (Toxin Technology,
ET404) in serum-free RPMI medium for 1 h at 37°C. JP-luc cells
were pretreated with DMSO, MB, or aPD1 antibody for 1 h before
mixing with SEE-loaded Raji or Raji-L1 cells at ratio of 1:1 in a 96-
well plate for 6 h. Luciferase activity was measured with a lumi-
nometer following the manufacturer’s instructions (Promega,
E2620).
For Fig 2H, JP-luc cells were co-cultured with Raji-L1 or parental
Raji cells in a 96-well plate precoated with 10 lg/ml of aCD3/aCD28
for 6 h and the supernatants were collected after 24 h. IL-2 was
quantified by ELISA using Human IL-2 ELISA kit (Mlbio, HX2390).
Quantification of protein–protein interaction
For experiments described in Fig 3D, we coated the wells of a 96-
well microtiter plate with 4 lg/ml of Y248-phosphorylated ITSM
version of PD-1 peptide (PEPPVPCVPEQTE(p-Y)ATIVFPSGMGTS-
SPAR, synthesized by GL Biochem Ltd.) in carbonate buffer by incu-
bating overnight at 4°C or 2–6 h at 37°C following instructions
provided by Peptide Coating Kit (Takara, MK100). After blocking
the wells with 5% BSA in PBS, recombinant hSHP2-FC (500 ng/ml,
R&D Systems, 1894-SH-100) protein was added in the presence of
phosphatase inhibitor cocktail and plates were incubated for 1 h at
RT. Horseradish peroxidase (HRP)-conjugated anti-FC Tag antibody
(1:5,000, Sino Biological, SSA001) was added in each well for 1 h,
and binding was quantified using a DuoSet Ancillary Reagent Kit
(R&D Systems, DY008).
For experiments described in figure Appendix Fig S3B, 96-well
microtiter plates were coated with Fc-tagged hPD-L1 protein (10 lg/
ml) or Fc-tagged mPD-L1 protein (10 lg/ml) overnight at 4°C. After
blocking, recombinant 6×His-tagged hPD-1 (500 ng/ml, Sino Biolog-
ical, 10377-H08H-50) or 6×His-tagged mPD-1 protein (500 ng/ml,
Sino Biological, 50124-M08H-100) was added and plates were incu-
bated for 1 h at RT. Horseradish peroxidase (HRP)-conjugated anti-
His antibody (1:5,000, BioLegend, 652504) was added in each well
for 1 h, and binding was quantified using a DuoSet Ancillary
Reagent Kit.
For experiments described in Fig EV3A and Appendix Fig S3A,
Jurkat-hPD-1 T-cell line (parental Jurkat cells served as negative
control) was incubated with 1 lg/ml of hPD-L1 protein (Fc-
tagged) in the presence of MB at indicated concentration at 4°C
for 30 min. Cells were stained with PE-conjugated anti-hIgG-Fc
antibody at 4°C for 1 h. Binding of hPD-L1 on cells was deter-
mined by flow cytometry.
Bimolecular fluorescence complementation assay
Jurkat cells were co-transfected with hPD1-C-Luc or PD1Y248F-C-Luc
and hSHP2-N-luc or hCD28-C-Luc or hCD28Y191F-C-Luc and hP85-N-
luc. After 24 h of rest, transfected cells were seeded in a 96-well
plate precoated with 10 lg/ml of aCD3/aCD28, with media with
10 lg/ml of hPD-L1 protein in the presence of MB at indicated
concentrations for 6 h followed by analysis of luciferase activity.
For experiments described in figure Appendix Fig S3T and U,
293T cells were co-transfected with plasmids encoding human
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EGFR-C-Luc or FGFR1-C-Luc and hSHP2-N-luc. After 36 h, the
transfected cells were seeded in a 96-well plate, treated with MB at
indicated concentrations for 6 h followed by analysis of luciferase
activity.
Confocal microscope analysis
Jurkat cells were co-transfected with hPD-1-EGFP and hSHP2-
mCherry. After resting for 24 h, transfected cells were seeded on
Poly-L-lysine-treated coverslips in 24-well plate. Cells were then
incubated with 10 lg/ml of hPD-L1 protein or 2 lM of pervanadate
(PVD) for 5 min in the presence of 100 nM or 1 lM of MB for 2 min
before fixing with 4% paraformaldehyde and staining with DAPI.
Colocalization signal was examined with confocal microphotograph
(bar = 2 lm).
Co-immunoprecipitation (co-IP)
For experiments described in Fig 3C, 293T cells were co-transfected
with constructs pCAGiN-PD-1 and pCDNA3.1-SHP2-FLAG for over-
expressing human PD-1 and human SHP2 (3 × FLAG-tagged). Cells
were incubated with 100 nM, 500 nM, or 1 lM of MB for 6 h, with
the last 5 min treated with 2 lM of PVD. Cells were harvested for
preparing the protein lysate using NP40 lysis buffer (125 mM Tris–
HCl, pH 7.4, 150 mM NaCl, 1% NP40, 1 mM EDTA, 5% glycerol,
1 mM PMSF, supplemented with Roche protease and PhosSTOP
phosphatase inhibitor cocktail). The lysates were subjected to co-
immunoprecipitation assay with anti-FLAG antibody (1:1,000,
SIGMA, F1804). Equal fractions of the immunoprecipitates were
subjected to SDS–PAGE and blotted with PD-1 antibody (1:1,000,
Cell Signaling Technology, 86163).
For experiments described in Fig 3E and Appendix Fig S3S, 293T
cells were co-transfected with human EGFR-C-Luc and SHP2-
3 × FLAG or FGFR1-3 × FLAG and SHP2-HA. After 36 h, transfected
cells were serum-starved for 12 h and then treated with complete
medium and MB for 2 h. Cells were harvested for preparing the
protein lysate using NP40 lysis buffer. The lysates were subjected to
co-immunoprecipitation assay with anti-FLAG antibody. Equal frac-
tions of the immunoprecipitates were subjected to SDS–PAGE and
blotted with anti-EGFR antibody (1:1,000, Abcam, E234,) or anti-HA
antibody (1:1,000, Santa Cruz, C1091).
Western blotting analysis of TCR signaling protein components
For experiments described in Fig 3E, mature OT-1 CTLs were
pretreated with 100 nM of MB. These cells were then seeded in 6-
well plate precoated with 10 lg/ml of aCD3/aCD28, with media
supplemented with 20 lg/ml of mPD-L1 protein and 100 nM of
MB for 2 min. Cells were harvested for preparing protein lysate
using NP40 lysis buffer. Equal fractions of the lysates were
subjected to SDS–PAGE and blotted with Phospho-Zap-70
(1:1,000, Cell Signaling Technology, 2717), ZAP70 (1:1,000, Cell
Signaling Technology, 3165), Phospho-PKCh (1:1,000, Cell Signal-
ing Technology, 9377), PKCh (1:1,000, Cell Signaling Technology,
13643), Phospho-PLCc1(1:1,000, Cell Signaling Technology,
14008), PLCc1(Cell Signaling Technology, 5690), Phospho-AKT
(1:1,000, Cell Signaling Technology, 4060S) and AKT (1:1,000,
Cell Signaling Technology 9272S).
Animal experiments
C57BL/6J mice were purchased from Beijing Vital River Laboratory
Animal Technology Co. Ltd.. CD45.1+ OT-1 transgenic mice of
C57BL/6J background, Rag1/ mice, and TetO-EGFR L858R/
CC10rtTA mice were kept in Institute of Laboratory Animal Science,
Jinan University. All wild-type and transgenic mice were age- and
sex-matched. All animals were housed in specific pathogen-free
conditions and breeding, and all animal procedures were conducted
in strict accordance with guidelines for the care and use of labora-
tory approved by the Institute of Laboratory Animal Science, Jinan
University.
C57BL/6J female mice (8 weeks) or Rag1/ female mice
(8 weeks) were injected with 2 × 106 EG7-L1 (s.c.) on the right
flank. After tumor growth up to 7 × 6 × 6 mm3 or after indicated
days postinoculation, mice were transferred with 2 × 106 OVA stim-
ulated CD45.1+ CTL cells (i.v.). Mice were randomized into 3
groups (n=5) for treatment with vehicle, 10 mg/kg of aPD-1 every
other day (BioXcell, BP0033-2) (i.p.), and 20 mg/kg/day (i.g.) of
MB (TargetMol, 7220-79-3). The tumor growth and tumor weight
were appropriately recorded.
EGFR L858R transgenic female mice (8 weeks) were generated
by microinjection and characterized. Lung cancer-bearing mice
were randomized into 3 groups (n = 5) for treating with vehicle,
MB, and aCD8/MB, respectively. Anti-CD8a (BioXcell, BE0061)
depleting antibody was injected (i.p.) at 200 mg per mouse every
other day for 2 weeks before combinational treatment with MB.
Tumor burdens were recorded through computed tomography
scanning. CT images (recorded by Pingseng Healthcare recorder
SNC-100) were analyzed blindly. Mice were sacrificed after the
treatment for 1 weeks. Lungs of these mice were prepared for
pathological or flow cytometry analysis.
Human peripheral blood mononuclear cell proliferation
Protocol was approved by ethnic committee of Jinan University.
Informed consent was obtained from all subjects, and the experi-
ments were conformed to the principles set out in the WMA Decla-
ration of Helsinki and the Department of Health and Human
Services Belmont Report.
Appendix data information
Exact P-values and statistical tests are listed in Appendix Table S1.
Dilutions for all the antibodies are listed in Appendix Table S2.
Expanded View for this article is available online.
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current antibody drugs used in clinic inhibit PD-1 function by blocking
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oping PD-1 inhibitors remain to be explored. (iii) Small molecular PD-
1 inhibitors targeting steps other than PD-1/PD-L1 interaction remain
to be explored.
Results
We set up a high-throughput screening system consisting of PD-1
expressing T cell and PD-L1 expressing antigen-presenting cell. Using
this system, we screened small chemical library for PD-1 inhibitors
and identified methylene blue (MB), an FDA-approved drug, as a
potent PD-1 inhibitor. Mechanistically, MB blocked recruitment of
SHP2 by PD-1 of T cell in response to stimulation by PD-L1 and thus
inhibited PD-1 signaling. MB potently restored proliferation, cytokine
expression, and cytotoxicity of cytotoxic T lymphocytes (CTL) in the
context of PD-1 signaling. MB effectively shrank tumor allografts or
autochthonous lung cancer in vivo. MB was also effective to enhance
human CTL function in vitro.
Impact
We have identified an FDA-approved chemical as a potent PD-1 inhi-
bitor, implicating immediate clinical application. Our data showed
that targeting PD-1/SHP2 interaction is a reasonable strategy for
developing PD-1 inhibitor, which sheds light on novel strategies to
develop PD-1 inhibitors.
16 of 17 EMBO Molecular Medicine e11571 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Zhenzhen Fan et al
Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT,
Daugherty CZ, Koenig L, Yu K et al (2017) Rescue of exhausted CD8 T cells
by PD-1-targeted therapies is CD28-dependent. Science 355: 1423 – 1427
Li H, Tao C, Cai Z, Hertzler-Schaefer K, Collins TN, Wang F, Feng G-S, Gotoh
N, Zhang X (2014) Frs2alpha and Shp2 signal independently of Gab to
mediate FGF signaling in lens development. J Cell Sci 127: 571 – 582
Li C, Zhang N, Zhou J, Ding C, Jin Y, Cui X, Pu K, Zhu Y (2018) Peptide
blocking of PD-1/PD-L1 interaction for cancer immunotherapy. Cancer
Immunol Res 6: 178 – 188
Marasco M, Berteotti A, Weyershaeuser J, Thorausch N, Sikorska J, Krausze J,
Brandt HJ, Kirkpatrick J, Rios P, Schamel WW et al (2020) Molecular
mechanism of SHP2 activation by PD-1 stimulation. Sci Adv 6: eaay4458
Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R (2018)
Venetoclax: a new wave in hematooncology. Exp Hematol 61: 10 – 25
Moore MW, Carbone FR, Bevan MJ (1988) Introduction of soluble protein into
the class I pathway of antigen processing and presentation. Cell 54:
777 – 785
Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated
myocarditis. Lancet 391: 933
Nagy Z, Comer S, Smolenski A (2018) Analysis of protein phosphorylation
using Phos-Tag gels. Curr Protoc Protein Sci 93: e64
Nishimura H, Minato N, Nakano T, Honjo T (1998) Immunological studies on
PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell
responses. Int Immunol 10: 1563 – 1572
Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of
lupus-like autoimmune diseases by disruption of the PD-1 gene encoding
an ITIM motif-carrying immunoreceptor. Immunity 11: 141 – 151
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M,
Drengler R, Chen C, Smith L, Espino G et al (2015) Phase I study of
pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients
with advanced solid tumors. Clin Cancer Res 21: 4286 –4293
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA,
Petrylak DP, Teng SL et al (2014) MPDL3280A (anti-PD-L1) treatment leads
to clinical activity in metastatic bladder cancer. Nature 515: 558 – 562
Ran X, Gestwicki JE (2018) Inhibitors of protein-protein interactions (PPIs): an
analysis of scaffold choices and buried surface area. Curr Opin Chem Biol
44: 75 – 86
Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y (2017) A versatile
system for rapid multiplex genome-edited CAR T cell generation.
Oncotarget 8: 17002 – 17011
Riley JL (2009) PD-1 signaling in primary T cells. Immunol Rev 229: 114 – 125
Rota G, Niogret C, Dang AT, Barros CR, Fonta NP, Alfei F, Morgado L, Zehn D,
Birchmeier W, Vivier E et al (2018) Shp-2 is dispensable for establishing T
cell exhaustion and for PD-1 signaling in vivo. Cell Rep 23: 39 – 49
Ruess DA, Heynen GJ, Ciecielski KJ, Ai J, Berninger A, Kabacaoglu D,
Gorgulu K, Dantes Z, Wormann SM, Diakopoulos KN et al (2018)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Nat
Med 24: 954 – 960
Santis AG, Campanero MR, Alonso JL, Tugores A, Alonso MA, Yague E, Pivel JP,
Sanchez-Madrid F (1992) Tumor necrosis factor-alpha production induced
in T lymphocytes through the AIM/CD69 activation pathway. Eur J
Immunol 22: 1253 – 1259
Shyu YJ, Hu CD (2008) Fluorescence complementation: an emerging tool for
biological research. Trends Biotechnol 26: 622 – 630
Skalniak L, Zak KM, Guzik K, Magiera K, Musielak B, Pachota M, Szelazek B,
Kocik J, Grudnik P, Tomala M et al (2017) Small-molecule inhibitors of PD-
1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-
cells. Oncotarget 8: 72167 – 72181
Theze J, Alzari PM, Bertoglio J (1996) Interleukin 2 and its receptors: recent
advances and new immunological functions. Immunol Today 17:
481 – 486
Tian R, Wang H, Gish GD, Petsalaki E, Pasculescu A, Shi Y, Mollenauer M,
Bagshaw RD, Yosef N, Hunter T et al (2015) Combinatorial proteomic
analysis of intercellular signaling applied to the CD28 T-cell costimulatory
receptor. Proc Natl Acad Sci USA 112: E1594 – E1603
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012) Safety,
activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J
Med 366: 2443 – 2454
Xia Y, Jeffrey Medeiros L, Young KH (2016) Signaling pathway and
dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim
Biophys Acta 1865: 58 – 71
Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma
M, Saito T (2012) Programmed cell death 1 forms negative costimulatory
microclusters that directly inhibit T cell receptor signaling by recruiting
phosphatase SHP2. J Exp Med 209: 1201 – 1217
Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Yasuda
Y, Funazo T, Hirai T (2018) Nivolumab in non-small-cell lung cancer with
EGFR mutation. Ann Oncol 29: 777 – 778
Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Domling A, Dubin G,
Holak TA (2016) Structural basis for small molecule targeting of
the programmed death ligand 1 (PD-L1). Oncotarget 7:
30323 – 30335
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
ª 2020 The Authors EMBO Molecular Medicine e11571 | 2020 17 of 17
Zhenzhen Fan et al EMBO Molecular Medicine
